Saturday 17 October 2026 Export CBUS’s income statement to Excel — free account

Cibus, Inc.

Cibus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, down 14.6% from fiscal 2024. In the quarter to June 2026, revenue grew 6.54%, EPS grew 52.5%, free cash flow grew 31.6% and total debt fell 62.1%, each against the same quarter a year earlier.

1.32 0.03 +2.33%

Follow CBUS

Alert me

Market cap: $98.6M
P/E: 0.0×
Fwd P/E: −1.4×
Dividend yield: —
F-score: 3/9
Altman Z: −4.83
Beneish M: −4.25
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	—	—	—	—	—	—	—	—	—	—	—	—

Insider Ownership 38.91%

Capital & Financial Ratios $m

Market Cap 98.59

Revenue 4.35

Net Income (99.62)

Free Cash Flow (46.28)

Net Debt (20.38)

Current Ratio 1.62

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (1.40)

P/S ratio 23.31

P/B ratio 6.84

Past 5Y EPS Growth —

This Y EPS Growth 69.54%

Next Y EPS Growth 24.80%

Next Y revenue growth 42.76%

Next 5Y EPS Growth 51.36%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 45.45%

10-year low 10-year high

P/B against its own 10 years 79.91%

10-year low 10-year high

EV/Sales against its own 10 years 44.21%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack
2017	Powerpack

special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	33	14	10	20
Receivables	1	1	1	1
Inventory	—	—	—	—
Other	—	—	—	—
	35	17	12	23

	2023	2024	2025	Q'26
Payables	6	6	8	6
ST’ Debt	—	—	—	—
Other	1	3	0	0
	21	20	17	14

Compound Annual Growth %

	10y	5y	3y
Sales	11.08%	(31.34%)	185.12%
Cash Flow	0.00%	0.00%	0.00%
Earnings	0.00%	0.00%	0.00%
Book Value	(1.05%)	(9.95%)	44.51%

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	2	1	—	—	—
’25	1	1	1	1	4
’24	1	1	2	1	4
’23	0	0	0	1	2
’22	0	0	0	0	0
’21	4	12	8	2	26
’20	2	2	5	14	24

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(11)	(9)	—	—	—
’25	(12)	(14)	(12)	(13)	(51)
’24	(13)	(17)	(14)	(14)	(58)
’23	(2)	(12)	(15)	(17)	(46)
’22	(6)	(5)	(4)	(4)	(19)
’21	(9)	(2)	(3)	(4)	(19)
’20	(12)	(13)	(5)	(13)	(44)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(12)	(9)	—	—	—
’25	(12)	(14)	(12)	(14)	(51)
’24	(14)	(17)	(14)	(14)	(59)
’23	(2)	(12)	(18)	(17)	(51)
’22	(7)	(6)	(5)	(4)	(21)
’21	(10)	(2)	(3)	(4)	(19)
’20	(13)	(14)	(6)	(13)	(45)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.33)	(0.29)	—	—	—
’25	(1.34)	(0.61)	(0.44)	(0.59)	(2.78)
’24	(1.12)	(1.14)	(7.63)	(0.87)	(10.83)
’23	(5.45)	(3.05)	(1.59)	(21.86)	(25.95)
’22	(6.50)	(2.50)	(6.50)	(3.00)	(18.50)
’21	(13.50)	(6.50)	(10.00)	(9.00)	(39.00)
’20	(17.00)	(16.50)	(14.50)	(18.50)	(66.00)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	463.00	441.50	177.50	120.00	102.00	6.25	6.65	2.35	1.09	Analyst estimates 2026–2028 Powerpack
	High	—	1,594.50	1,361.50	964.75	420.50	621.50	125.50	38.85	23.18	3.40
People
People	Employees	27	35	50	75	59	55	48	183	159	118
	Revenue/emp, $m	0.01	0.01	0.00	0.10	0.40	0.47	0.00	0.01	0.03	0.03
Income, $m
Income, $m	Revenue	0	1	0	7	24	26	0	2	4	4
	Gross margin, %	49.87	100.00	100.00	(27.19)	(47.28)	(9.89)	100.00	100.00	100.00	100.00
	EBT	(12)	(26)	(28)	(40)	(45)	(29)	(17)	(338)	(283)	(132)
	EBT margin, %	(3,029.07)	(5,114.17)	(11,820.76)	(542.93)	(187.98)	(112.36)	(10,758.60)	(18,582.44)	(6,632.66)	(3,632.10)
	Net income	(12)	(26)	(28)	(40)	(45)	(29)	(17)	(338)	(283)	(132)
	Depreciation	0	1	1	2	2	2	2	254	188	27
Per share, $
Per share, $	Revenue	1.02	1.10	0.38	11.12	35.20	34.67	0.17	0.18	0.18	0.08
	Earnings	(30.83)	(56.00)	(45.50)	(60.50)	(66.00)	(39.00)	(18.50)	(25.95)	(10.83)	(2.78)
	Cash flow	(23.56)	(27.61)	(32.92)	(48.70)	(64.45)	(25.10)	(21.05)	(4.48)	(2.50)	(1.11)
	Capex	(26.59)	(1.68)	(3.01)	(4.53)	(2.64)	(0.66)	(1.65)	(0.42)	(0.03)	(0.01)
	Free cash flow	(50.16)	(29.29)	(35.93)	(53.22)	(67.09)	(25.76)	(22.70)	(4.90)	(2.53)	(1.12)
	Book value	33.47	124.11	152.19	95.27	54.42	18.86	7.86	28.45	3.97	0.48
	Shares, m	0	0	1	1	1	1	1	10	23	46
Valuation, ×
Valuation, ×	P/E	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	P/S	20.73	1,068.87	1,347.02	31.52	5.99	3.07	38.97	104.23	15.15	21.88
	P/B	1.29	9.45	3.40	3.68	3.88	5.65	0.85	0.65	0.70	3.65
	EV/Sales	15.39	977.30	1,025.21	25.98	5.59	3.21	105.11	87.14	19.37	19.45
	EV/FCF	(0.61)	(36.60)	(10.97)	(5.43)	(2.93)	(4.32)	(0.79)	(3.13)	(1.40)	(1.38)
Cash, $m
Cash, $m	Operating cash flow	(9)	(13)	(20)	(32)	(44)	(19)	(19)	(46)	(58)	(51)
	Capex	(10)	(1)	(2)	(3)	(2)	0	(2)	(4)	(1)	(1)
	Free cash flow	(20)	(14)	(22)	(35)	(45)	(19)	(21)	(51)	(59)	(51)
Balance, $m
Balance, $m	Working capital	3	53	89	56	33	10	2	14	(3)	(5)
	Total debt	2	10	18	18	19	18	13	1	31	30
	Net debt	(5)	(47)	(76)	(41)	(10)	3	10	(32)	17	20
	Shareholders’ equity	13	57	93	63	37	14	7	293	92	22
Returns, %
Returns, %	ROA	(56.72)	(58.52)	(29.22)	(38.29)	(59.22)	(58.10)	(56.67)	(94.43)	(56.21)	(38.80)
	ROIC	(93.51)	(147.06)	(100.70)	(113.98)	(101.92)	(105.87)	(81.50)	(76.24)	(147.93)	(145.89)
	ROE	(64.67)	(73.60)	(36.98)	(50.82)	(90.23)	(114.49)	(158.12)	(178.00)	(130.38)	(222.98)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
UNCY Unicycive Therapeutics, Inc.	$100.0M	— (loss-making)	— (loss-making)	—	n/m	+9.77% (above 0%: growing)	0.00%	0.00%	Compare
BDTX Black Diamond Therapeutics, Inc.	$100.0M	— (loss-making)	— (loss-making)	—	n/m	+12.91% (above 0%: growing)	100.00%	0.00%	Compare
PYPD PolyPid Ltd.	$99.5M	— (loss-making)	—	—	n/m	−64.96% (below 0%: shrinking)	0.00%	0.00%	Compare
MIST Milestone Pharmaceuticals Inc.	$98.9M	— (loss-making)	— (loss-making)	−62.73% (below 0%: shrinking)	n/m	−80.81% (below 0%: shrinking)	94.28%	(4,584.97%)	Compare
CBUS Cibus, Inc.	$98.6M	— (loss-making)	— (loss-making)	+6.54% (above 0%: growing)	n/m	+31.62% (above 0%: growing)	100.00%	(1,300.30%)
PMVP PMV Pharmaceuticals, Inc.	$97.4M	— (loss-making)	—	—	n/m	+20.27% (above 0%: growing)	0.00%	0.00%	Compare
NRXS Neuraxis, Inc.	$97.2M	— (loss-making)	— (loss-making)	+115.71% (above 0%: growing)	n/m	+29.76% (above 0%: growing)	85.87%	(110.16%)	Compare
IMUX Immunic, Inc.	$96.9M	— (loss-making)	—	—	n/m	−26.79% (below 0%: shrinking)	0.00%	0.00%	Compare
ATRA Atara Biotherapeutics, Inc.	$96.9M	— (loss-making)	— (loss-making)	−96.42% (below 0%: shrinking)	n/m	+52.10% (above 0%: growing)	69.68%	(749.21%)	Compare
Median of peers	$98.2M	—	—	−62.73%	—	+11.34%	34.84%	0.00%

All 614 Biotechnology stocks →

Cibus, Inc. (CBUS) key facts

Concern: Cibus, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.6 million, down 14.6% from fiscal 2024.
Cibus, Inc. (CBUS) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, CBUS traded at $1.32, a market capitalization of $98.6 million.
Return on equity was −223.0% and debt-to-equity 0.00.
Its Piotroski F-score is 3 out of 9 and its Altman Z-score is −4.83 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.